Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO5428029 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| A1 Healthy Volunteers | EXPERIMENTAL | - |
| A2 | PLACEBO_COMPARATOR | - |
| B1 HCV Infection | EXPERIMENTAL | - |
| B2 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| RO5428029 | DRUG | Multiple ascending doses |
| placebo | DRUG | multiple doses |
Inclusion Criteria: * Healthy subjects (Part A) or patients with chronic hepatitis C infection (Part B), 18 to 60 years of age, inclusive * Body mass index (BMI) between 18 and 32 kg/m2, inclusive, and a minimum weight of 45 kg * Female subjects/patients must be surgically sterile or post-menopausa...
RO5428029 is an investigational small molecule developed by Roche Holding AG for chronic hepatitis C. It is in Phase 1 clinical development and has been studied in a single completed trial that enrolled 42 participants, including healthy volunteers and patients with chronic hepatitis C.
RO5428029 is being developed for the treatment of chronic hepatitis C, an infectious disease of the liver. It is an investigational agent and has not been approved for any indication. Its only reported clinical study enrolled patients with chronic hepatitis C alongside healthy volunteers.
RO5428029 is developed by Roche Holding AG, which trades under the ticker RHHBY. Roche is the sponsor of the compound's clinical program in chronic hepatitis C.
RO5428029 is in Phase 1 clinical development. It is investigational and has not been approved by the FDA or any other regulatory agency. The program's single reported trial has been completed, and no active trials are currently listed.
RO5428029 has been studied in one completed Phase 1 trial, NCT01371162, titled A Study of RO5428029 in Healthy Volunteers and Patients With Chronic Hepatitis C. The trial enrolled 42 participants across France, the Netherlands, and Poland, was randomized, double blind, and placebo controlled, and included adults 18 years and older.